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We have produced a new Ebola virus pseudotype: E-S-FLU, which can be handled in 16 
biosafety level-1/2 containment for laboratory analysis. E-S-FLU is a single cycle 17 
influenza virus coated with Ebolavirus glycoprotein, and it encodes enhanced green 18 
fluorescence protein as a reporter that replaces the influenza haemagglutinin. MDCK-19 
SIAT1 cells were transduced to express Ebolavirus glycoprotein as a stable 20 
transmembrane protein for E-S-FLU production. Infection of cells by E-S-FLU was 21 
dependent on Niemann-Pick C1 protein, which is the well-characterized receptor for 22 
Ebola virus entry at the late endosome/lysosome membrane. E-S-FLU was neutralized 23 
specifically by anti-Ebola glycoprotein antibody and a variety of small drug molecules 24 
that are known to inhibit entry of wild-type Ebola virus. To demonstrate the application 25 
of this new Ebola virus pseudotype, we show that a single laboratory batch was 26 
sufficient to screen a library (LOPAC®1280 Sigma) of 1280 pharmacologically active 27 
compounds for inhibition of virus entry. 215 compounds inhibited E-S-FLU infection, 28 
while only 22 inhibited the control H5-S-FLU virus coated in an H5 haemagglutinin. 29 
These inhibitory compounds have very dispersed targets and mechanisms of action e.g. 30 
calcium channel blockers, estrogen receptor antagonists, anti-histamines, serotonin 31 
uptake inhibitors etc. and this correlates with inhibitor screening results with other 32 
pseudotypes or wild-type Ebola virus in the literature. E-S-FLU is a new tool for Ebola 33 
virus cell entry studies and is easily applied to high throughput screening assays for 34 
small molecule inhibitors or antibodies.  35 
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Ebola virus is from the Filoviridae family and is a biosafety level 4 pathogen. There are 37 
no FDA-approved therapeutics for Ebola virus. These characteristics warrant the 38 
development of surrogates of Ebola virus that can be handled in more convenient 39 
laboratory containment to study the biology of the virus, and screen for inhibitors. Here 40 
we characterized a new surrogate named E-S-FLU, that is based on a disabled 41 
influenza virus core coated with the Ebola virus surface protein, but does not contain 42 
any genetic information from the Ebola virus itself. We show that E-S-FLU uses the 43 
same cell entry pathway as wild-type Ebola virus. As an example of the ease of use of 44 
E-S-FLU in biosafety level-1/2 containment, we showed that a single production batch 45 
could provide enough surrogate virus to screen a standard small molecule library of 46 
1280 candidates for inhibitors of viral entry.  47 
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Ebola virus is a filamentous RNA virus that belongs to the Filoviridae family (1). It has a 49 
negatively stranded RNA genome (19kb) that encodes 7 genes. Ebola virus is a 50 
zoonotic virus and the mechanism by which is it maintained in its natural reservoirs such 51 
as fruit bats is not fully understood (2). The first Ebola outbreak in the human population 52 
happened in Congo and Sudan in 1976. During the Ebola outbreak, Zaire ebolavirus 53 
was first isolated and characterized (3, 4). Since then, five species of ebolavirus have 54 
been identified: Zaire, Sudan, Taï Forest, Bundibugyo and Reston (5). Ebola virus is 55 
highly infectious in human and non-human primates, and causes a haemorrhagic fever 56 
with a fatality rate of 25-90% (1). The recent epidemic in 2014-2015 caused nearly 57 
30,000 human infections and more than 11,000 deaths in West Africa (World health 58 
organization, March 2016). So far, there is no FDA-approved treatment or vaccine 59 
against Ebola virus disease, but the recombinant VSV-GP vaccine has shown very 60 
promising protection in the Guinea ring vaccination trial (6).  61 
 62 
Although much attention has been drawn to Ebola virus research since then, direct 63 
handling of Ebola virus is limited to biosafety level 4 laboratories. Development of a safe 64 
substitute is very important and useful for high-throughput screening of therapeutics, 65 
diagnostic screening of neutralizing human sera, and understanding the entry 66 
mechanism of Ebola virus.  67 
 68 
Ebola virus is a lipid-enveloped virus, and the glycoprotein (EBOV-GP) is the only 69 
protein presented at the virus surface. EBOV-GP plays an important role in virus cell 70 
entry, and it is the key target for neutralisation by antibodies (7). Currently available viral 71 
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surrogates for EBOV, such as EBOV-GP pseudotyped lentivirus (8) and vesicular 72 
stomatitis virus (VSV) (9), expose EBOV-GP at the viral surface. However, EBOV-GP 73 
pseudotyped viruses are still different from wild-type Ebola virus, and vary in their 74 
biological properties and susceptibility to neutralizing antibodies. Recently the National 75 
Institute of Biological Standards and Control (NIBSC) has compared 22 different Ebola-76 
based in vitro assays with the wild-type Ebola virus for neutralization by a panel of 77 
antibodies and sera. The results showed variable but generally poor correlations (10). 78 
Therefore, designing and comparing additional EBOV-GP pseudotyped viruses is 79 
important to accurately determine the correlates of protection. 80 
 81 
Here we describe a new Ebola virus pseudotype (E-S-FLU) based on a non-replicating 82 
influenza virus S-FLU (11). Influenza virus is also a negatively stranded RNA virus. S-83 
FLU has its haemagglutinin gene replaced by an enhanced green fluorescence protein 84 
(eGFP) reporter. We found that unlike other cell lines (12–19), MDCK-SIAT1 can stably 85 
express high levels of EBOV-GP without apparent toxicity. Pseudotyping is done by 86 
simply infecting MDCK-SIAT1 producer cell lines (20) that are stably transduced to 87 
express EBOV-GP, with seed S-FLU virus. The expression of the EBOV-GP in the 88 
producer cell line complements the defect in haemagglutinin expression, and the S-FLU 89 
replicates to levels sufficient to perform drug inhibition or antibody neutralization assays 90 
without further concentration. The stable producer cell line allows easy production of E-91 
S-FLU without the need of repeated transfection for each round of virus production, in 92 
comparison to lentivirus pseudotyping and VSV psueodypting methods. E-S-FLU does 93 
not contain any genetic materials from the Ebola virus and can infect cell lines that do 94 
not express EBOV GP or influenza HA for only a single cycle. Therefore, it can be 95 
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handled at biosafety level 1/2. We have shown that E-S-FLU is easy to produce, and it 96 
resembles Ebola virus during the cell entry process. We also compared E-S-FLU with 97 
recombinant wild-type Ebola virus in drug screening assays, and the results were highly 98 
correlated. E-S-FLU is a useful surrogate for Ebola virus in vitro studies.   99 
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Generation of EBOV-GP pseudotyped S-FLU 101 
S-FLU is a pseudotyped influenza virus with its endogenous haemagglutinin sequence 102 
removed, and it was previously pseudotyped with different subtypes of influenza 103 
haemagglutinin (11, 21). In order to incorporate EBOV-GP in the S-FLU envelope, we 104 
used a lentiviral vector to transduce MDCK-SIAT1 cells to express full length Zaire 105 
strain EBOV-GP gene (Zaire wt/GIN/2014/ Kissidougou-C15). Transduced cells were 106 
healthy in morphology (Fig. 1). EBOV-GP was expressed at the cell surface and can be 107 
detected by GP-specific monoclonal antibody KZ52. Cells with high expression of 108 
EBOV-GP were sorted and stored as the E-SIAT cell line. GP surface expression was 109 
not toxic to MDCK-SIAT1 cells, and the expression is stable and uniform up to at least 110 
the ninth passage (Fig. 1).  111 
 112 
Cloned seed S-FLU virus that is coated in influenza haemagglutinin (HA) was added to 113 
propagate in E-SIAT cells to produce EBOV-GP pseudotyped S-FLU. After 48 hours 114 
culture supernatants were harvested and titrated on indicator MDCK-SIAT1 cells for 115 
infection. Infected MDCK-SIAT1 cells express eGFP that is encoded in the virus. We 116 
named the new pseudotype E-S-FLU. E-S-FLU reaches a lower titer compared to 117 
viruses grown in the H5 HA transduced producer cells and forms small diffuse plaques 118 
compared to H5-S-FLU (Fig. 2C) (21). Typical EC50 dilutions for E-S-FLU at 48 hours 119 
were ~1:8 compared to ~1:500 for H5-S-FLU (Fig. 2A). From the EC50 dilution, and the 120 
number of cells per well (3x104), the Cell Infectious Dose 50% (CID50/ml) in the E-S-121 
FLU batch was calculated as ~2X106 CID50/ml, H5 S-FLU as ~1.6x108 CID50/ml. 122 
However, the harvested culture supernatant from E-SIAT cells contains adequate 123 
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pseudovirions for 50 μl of a 1:4 dilution to give close to full infection of the 3x104 cells in 124 
a well of a 96-well plate. No further purification or concentration steps are needed for 125 
screening inhibitory drugs or antibodies. With the same protocol, we were also able to 126 
pseudotype S-FLU with Bundibugyo, Sudan and Mayinga-Zaire EBOV-GP to similar 127 
viral titers (data not shown).  128 
 129 
It has been shown in the literature that the transmembrane and cytoplasmic domain of 130 
Influenza HA is important for flu viral particle assembly (22-29). To potentially improve 131 
the viral titer of E-S-FLU, we designed a GP-HA hybrid protein, which contains the 132 
extracellular domain of the EBOV-GP and the transmembrane and cytoplasmic domain 133 
of HA. After transduction and sorting, GP-HA protein can be detected by antibody KZ52 134 
at the surface of EH-SIAT cells at the similar level as the E-SIAT cells. However, to our 135 
surprise, no infective S-FLU was detected from the EH-SIAT cell supernatant (data not 136 
shown).  137 
 138 
E-S-FLU infection requires NPC1 as receptor  139 
NPC1 protein has been identified as the key entry receptor for Ebola virus at the level of 140 
late endosome/ lysosome membrane (30-32). We infected both wild-type HeLa cells 141 
and two NPC1 knockout HeLa cell lines (ex2 NPC1-KO and ex4 NPC1-KO) (33) using 142 
E-S-FLU and H5-S-FLU (Fig. 3). Wild-type HeLa cells were infected by E-S-FLU and 143 
expressed eGFP. E-S-FLU infection was completely blocked in NPC1-KO cells. In 144 
contrast, percentage infection by H5-S-FLU were the same for wild-type and NPC1-KO 145 
cells. This shows that E-S-FLU requires NPC1 for cell entry, which resembles the wild-146 
type Ebola virus cell entry mechanism.  147 
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 E-S-FLU is specifically neutralized by EBOV-GP antibody 149 
To further validate our new EBOV-GP pseudotyped E-S-FLU, we tested it in the 150 
antibody micro-neutralization assay in comparison to control pseudotype H5-S-FLU and 151 
EBOV-GP coated lentivirus pseudotype (GP-lentivirus). H5-S-FLU contains exactly the 152 
same S-FLU core as E-S-FLU but differs at the surface glycoprotein. GP-lenti is a 153 
lentivirus pseudotyped with the full length Zaire-strain EBOV-GP 154 
(wt/GIN/2014/Kissidougou-C15), matched to E-S-FLU. 155 
 156 
Neutralization profiles for two antibodies are shown in Fig. 4. KZ52 is a human 157 
monoclonal antibody that specifically binds to Zaire species of EBOV-GP, and 158 
recognizes a conformational epitope at the base of GP (34, 35). KZ52 neutralized E-S-159 
FLU and GP-lenti pseudotyped virus with a similar EC50 value to what has been 160 
reported on wild-type Ebola virus (300 ng/ml, (34)), while it did not neutralize H5-S-FLU. 161 
The neutralization effect was confirmed by fluorescence microscopy (Fig 4E and 4F). In 162 
contrast, 21D85A, a H5 specific monoclonal antibody, neutralized H5-S-FLU but did not 163 
neutralize E-S-FLU or GP-lenti pseudotyped virus. This shows that the E-S-FLU 164 
pseudotyped virus we produced is coated with correctly folded EBOV-GP, and requires 165 
this molecule to infect the MDCK-SIAT1 indicator cells. These results show that E-S-166 
FLU can be used to screen for neutralizing antibodies to Ebola virus. 167 
 168 
Inhibition of E-S-FLU infection by small molecules 169 
In the literature, several drug screen studies have been done with wild-type Ebola virus 170 
(36-40) and Ebola virus surrogates such as Ebola viral like particles (41), EBOV-GP 171 
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pseudotyped rVSV (31) and lentivirus (42, 43). It was shown that drug molecules with 172 
diverse pharmacological functions have inhibited Ebola virus infection in vitro. To verify 173 
the use of E-S-FLU in drug screening assays, we selected several types of drug 174 
molecules that have been tested repeatedly in the literature and screened them against 175 
E-S-FLU in our drug inhibition assay. Table 1 summarizes the 13 initial inhibitors we 176 
have tested. E-S-FLU infection was effectively blocked by different groups of drugs, and 177 
the IC50 values were in the same range as those in the literature.  178 
 179 
All screens in Table 1 were repeated at least 3 times to calculate the geometric mean 180 
and 95% confidence interval of IC50. IC50 value is the drug concentration at which the 181 
eGFP fluorescence was reduced by 50%. We have also screened these drugs against 182 
H5-S-FLU (supplementary table S1). Most of them did not inhibit H5-S-FLU, except 183 
Niclosamide at 2.64μM. Fig. 5 shows an example of drug inhibition by Tetrandrine. 184 
Infection level was quantified by eGFP expression. We also estimated the toxicity for 185 
each drug by staining the cells with fluorescently labelled-wheat germ agglutinin (WGA) 186 
after infection, fixation and wash. WGA is a lectin that binds to cell surface N-acetyl-D-187 
glucosamine and sialic acid. Cells in good condition will remain adhered to the plate 188 
during analysis, and can be detected by WGA. Dead cells or unhealthy cells will detach 189 
and be washed away. WGA staining allows quick indication of drug toxicity in high-190 
throughput plate screening assays. This is verified by light microscopy (Fig. 5C and 5D). 191 
 192 
We have shown the calculated logP and pKa values of these inhibitors in Table 1. As 193 
found by others, many of the drug molecules that inhibited Ebola virus have high logP 194 
and high pKa values (e.g. Amiodarone, Verapamil, Clomiphene) and can be classified 195 
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as cationic amphipathic drugs (36, 44). There are also non-cationic amphiphiles that 196 
inhibited Ebola virus entry, such as EIPA: 5-(N-Ethyl-N-isopropyl Amiloride (45) and 197 
MDL28170 (42, 46), E64 (43, 47–49) and Niclosamide (41). The potential mode of 198 
action of each of these molecules is shown in Fig. 8. 199 
 200 
LOPAC®1280 library screen 201 
Having established that infection by E-S-FLU was dependent on NPC1 receptor, and 202 
was inhibited by specific antibodies and established small molecules, we proceeded to 203 
a formal drug screen. We have screened 1280 drug molecules from the LOPAC®1280 204 
library (Sigma-Aldrich) in our drug inhibition assay to test their effect on E-S-FLU and 205 
H5-S-FLU infection. This library contains 1280 pharmacologically active small 206 
molecules with different molecular targets. All drugs were screened in the first round at 207 
100 μM and 5 μM. Selected drugs were then titrated once in drug inhibition assay to 208 
calculate their IC50.  209 
 210 
In total, 215 out of 1280 molecules inhibited E-S-FLU infection to some level before 211 
reaching their toxicity in vitro (Fig. 6, 7 and supplementary table S1). Out of the 215 that 212 
inhibited E-S-FLU, 58 had an IC50 of less than 10 μM. In comparison, only 22 of the 213 
1280 molecules inhibited H5-S-FLU and 8 had IC50 of less than 10 μM. All of these 22 214 
molecules (Table 3) also inhibited E-S-FLU, and thus were likely to be acting either on 215 
both EBOV-GP and Influenza HA, or at a post entry stage that is independent of the 216 
surface glycoprotein. We did not see any molecule that inhibited H5-S-FLU but did not 217 
inhibit E-S-FLU. The detailed profile for all the inhibitors is shown in the supplementary 218 
table S1. These 215 inhibitors come from a variety of pharmacological groups according 219 
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to the description on Sigma’s website (Fig. 6). The table S1 also includes 13 small 220 
molecules tested in addition to the LOPAC1280 library to give a total of 228 inhibitors of 221 
E-S-FLU and of these, 25 that inhibited both E-S-FLU and H5-S-FLU (Fig. 7, Table 3).  222 
 223 
In our screening system, we quantified infection by measuring the overall fluorescence 224 
level of cells. Under the fluorescence microscope, it was clear that most drugs reduced 225 
the number of fluorescent cells (i.e. reduced the proportion of infected cells) as the drug 226 
concentration increased. 12 drugs however, caused a reduced overall fluorescence 227 
level of infected cells without reducing the number of fluorescent cells significantly. All 228 
these 12 drugs also affected H5-S-FLU infection. This suggests that they acted at a 229 
post entry phase, by limiting the expression of viral proteins. In Table 3, they are 230 
annotated as the “dimmer” drugs. The other 13 molecules that inhibited both E-S-FLU 231 
and H5-S-FLU reduced the number of infected cells, and thus may have affected the 232 
function of both glycoproteins. 233 
 234 
The IC50 of all 228 molecules that have inhibited E-S-FLU were plotted in Fig. 7. These 235 
include the 215 inhibitors from the LOPAC®1280 library together with the additional 13 236 
individual drugs we have tested in addition to this library. 237 
 238 
Comparison with Johansen et al., screen  239 
We compared our screening results with a recently published drug screening paper 240 
from Johansen et al., (39), in which wild-type EBOV was used to screen for inhibitors. 241 
There are 538 drugs in common between the two libraries (Table 2). 442 had agreed 242 
results; out of which 23 drugs were inhibitors and 419 showed no effect. For the rest of 243 
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the drugs, 70 were positive in LOPAC®1280 screen only, and 26 were positive in 244 
Johansen’s screen only. We performed a two-tailed Fisher’s exact statistical analysis on 245 
the comparison, and the correlation is significant (P value < 0.0001).   246 
 247 
One of the main differences between the two screens is the range of drug concentration 248 
being tested. The highest concentration tested in the Johansen’s screen was 13 μM 249 
whereas in our screen most drugs have been screened with concentrations higher than 250 
50μΜ if toxicity is not reached. For this reason, the great majority of “agreements” 251 
occurred in the drugs with IC50 less than 10μM in our assay (Table S1). For the drugs 252 
that were positive in LOPAC®1280 screen only, we selected Ebastine (E9531), 253 
Imipramine (I7379), Verapamil (V4629) and ordered them individually from Sigma to 254 
confirm their inhibitory effect. All three drugs showed the inhibitory effect on E-S-FLU 255 
with comparable IC50 as the LOPAC®1280 library screen. All 3 drugs have been 256 
reported as inhibitors in other papers (31, 36, 41). 257 
 258 
From the 26 drugs that were positive in Johansen’s screen but negative in our 259 
LOPAC1280 screen, we have ordered individually from Sigma and further tested 14 260 
drugs: Auranofin (Sigma code: A6733), Bepridil (B5016), Calcimycin (C7522), D609 261 
(T8543), Diphenyleneiodonium (D2926), Doxylamine (D3775), Linezolid (PZ0014), 262 
Naproxen (M1275), Nocodazole (M1404), Perphenazine (P6402), Rotenone (R8875), 263 
Sanguinarine (S5890), Serotonin (H9523) and Thapsigargin (T9033).  264 
 265 
Bepridil (a calcium channel inhibitor) and Perphenazine (a cationic amphiphile) from the 266 
LOPAC®1280 library did not inhibit E-S-FLU, but the individually ordered samples 267 
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showed specific inhibition to E-S-FLU (Bepridil IC50=2.7 μM, Perphenazine IC50=8.2 268 
μM). This indicates some variation due to false negatives in the library preparation from 269 
Sigma.  270 
 271 
D609, Doxylamine, Disopyramide, Linezolid, Naproxen, Rotenone and Sanguinarine 272 
were confirmed as non-inhibitors for E-S-FLU in our assay up to 100 μM. Auranofin, 273 
Calcimycin, Diphenyleneiodonium, Nocodazole and Thapsigargin were toxic to MDCK-274 
SIAT1 cells even at 0.2 μM, yet some cells were still infected. None of the drugs that are 275 
further tested inhibited H5-S-FLU.  276 
 277 
Discussion  278 
The design of E-S-FLU was based on a pseudotyped influenza virus, S-FLU that was 279 
previously developed in our group and is similar to other single cycle influenza 280 
pseudotypes (11, 21, 50). E-S-FLU is a non-replicating pseudotyped virus and can be 281 
manipulated at biosafety level 1/2 as it does not encode any genetic information from 282 
Ebola Virus. For ease of production we found that the MDCK-SIAT1 cell line (20) can 283 
stably express full length EBOV-GP without toxicity. Although replication of the S-FLU 284 
core in the EBOV-GP transduced cell line is 2 to 3 orders of magnitude less efficient 285 
than in the H5 HA expressing cells (Fig. 2), production of the pseudotype at a scale 286 
sufficient for high throughput assays is simple and efficient. E-S-FLU encodes eGFP as 287 
a reporter in preference to firefly luciferase, or beta-lactamase (9, 51, 52). Enzyme 288 
reporters are much more sensitive than eGFP, and very low-level infection can be 289 
amplified and detected. However, cells have to be lysed to release the enzymes, and 290 
then substrate is added for one round read-out only. In comparison, for drug inhibition 291 
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and neutralization assays S-FLU can be added to indicator cells at a MOI >=1 to 292 
produce bright eGFP fluorescence in the majority of cells that is stable over months 293 
after fixation, and can be measured in a plate reader or observed in the microscope 294 
without further manipulation (Fig. 4, 5).  295 
 296 
To validate E-S-FLU as a useful surrogate for Ebola virus, we showed that infection is 297 
fully dependent on the NPC1 receptor (Fig. 3), is inhibited by EBOV-GP specific 298 
antibody KZ52 (34, 35) (Fig. 4), and is also inhibited by a well characterized set of 299 
thirteen drugs that are thought to act at various points during viral entry (36-38, 40, 41) 300 
(Table 1, Fig. 8). 301 
 302 
Several laboratories have observed that a wide variety of FDA-approved drugs can 303 
inhibit infection of cell lines in vitro by Ebola virus (39, 41). We have screened 1280 304 
drugs from the LOPAC®1280 library to identify pharmacologically active small molecules 305 
that inhibit E-S-FLU cell entry. H5-S-FLU was tested in parallel to E-S-FLU to 306 
differentiate inhibition specific to EBOV-GP or to the S-FLU core. We identified 215 307 
molecules from the library that inhibited E-S-FLU, whereas only 22 inhibited H5-S-FLU, 308 
all of which also inhibited E-S-FLU. Therefore the inhibitory effects of 193 drugs were 309 
EBOV-GP dependent.  310 
 311 
We compared our screening result with the list of drugs screened by Johansen et al., 312 
(39), who screened 2635 small molecules on GFP expressing Ebola virus. 538 small 313 
molecules overlapped between the two libraries (Johansen vs. LOPAC®1280). Out of 314 
these overlaps, 442 molecules had concordant results between the two screens. 315 
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Correlation was statistically significant (P value < 0.0001). It is noteworthy that we 316 
identified at least 17 calcium channel inhibitors as specific inhibitors of E-S-FLU 317 
infection. Independent evidence exists for a possible role for calcium channels in the 318 
lysosomal membrane in viral entry (36, 37), perhaps through an effect on vesicle fusion 319 
(31, 53, 54). Recent studies suggested that two-pore channel 2 (TPC-2), a lysosomal 320 
calcium channel, is involved in the Ebola virus entry process, and this could be the 321 
target for the calcium channel inhibitors (37, 55).  322 
 323 
A large group of inhibitors share a common cationic amphiphilic feature, i.e. a 324 
hydrophilic end, usually a weak base amine group (high pKa) and a hydrophobic end 325 
(high logP), and are therefore likely to concentrate in lysosomes (56-58). The 326 
mechanism by which these drugs inhibit Ebola virus entry is not resolved (36, 38). 327 
Some cationic amphiphilic drugs can cause an increase in cholesterol accumulation in 328 
endosome and lysosome where EBOV-GP membrane fusion occurs. Others can 329 
influence the lysosomal membrane stability and indirectly inhibit Acid 330 
Sphingomyelinase, which are also known as Functional Inhibitors of Acid 331 
Sphingomyelinase (FIASMAs) (59, 60), and may have an indirect effect on calcium 332 
mobilization from the lysosome through the accumulation of sphingosine. In addition the 333 
most powerful member of the cationic amphiphilic group, Toremifene, has been shown 334 
to bind to a hydrophobic pocket in the EBOV-GP and destabilize the molecule in vitro 335 
(61), and so may have two sites of action.  336 
 337 
Many of these drugs have been identified to have a risk of causing long-QT syndrome, 338 
such as Amiodarone, Toremifene, Clarithromycin (62, 63). Inhibition of the potassium 339 
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channel hERG (human ether-a-go-go) in cardiac myocytes is commonly associated with 340 
long-QT syndrome (64). After comparing the 228 drugs that inhibited E-S-FLU in our 341 
studies with the hERG screening literature (64-66), we identified at least 46 (20.2% 342 
indicated in Table S1) as confirmed inhibitors of the hERG channel and hence may 343 
have this dangerous side-effect on cardiac conduction. The majority of these hERG 344 
binders are typical Cationic Amphipathic Drugs. It is unclear whether the features that 345 
inhibit Ebola virus entry also predispose to the effect on hERG binding and lengthening 346 
of the Q-T interval. Further dissecting their mechanisms of action is therefore necessary 347 
before administering them to Ebola virus infected patients, despite the fact that they are 348 
FDA-approved drugs (67, 68). As more potential mechanisms of action of these drugs 349 
are uncovered, testing combinations that act at different sites for synergistic effects may 350 
be valuable to reduce this risk (69, 70). 351 
 352 
One advantage of our S-FLU pseudotype is that infected cells express eGFP and 353 
fluoresce brightly. Visual inspection of cells in the assay plates by fluorescence 354 
microscopy revealed that two forms of inhibition could be distinguished. In the majority 355 
of cases the drugs reduced the number of infected cells. All of the 203 drugs that acted 356 
in an EBOV-GP dependent manner reduced the number of infected cells, which is 357 
consistent with inhibition of viral entry (Supplementary table S1). By contrast, in some 358 
cases the drugs did not reduce number of infected cells, but reduced the intensity of 359 
fluorescence expression in the infected cell population. Of the 228 drugs tested, 12 360 
reduced fluorescence intensity (Table 3). All of these also inhibited H5-S-FLU. In 361 
general the IC50s for these agents were similar for E-S-FLU and H5-S-FLU, which is 362 
consistent with them acting on functions controlled by the influenza core, which is 363 
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common to both. We suggest that they affect the virus at a post-entry level like 364 
Faviparivir, a specific inhibitor of RNA-dependent RNA polymerase (71-74), which was 365 
initially synthesized to inhibit influenza virus but later found effective against Ebola virus 366 
in vitro. In addition Aminopterin, a dihydrofolate reductase inhibitor; Brequinar, a 367 
dihydroorotate dehydrogenase inhibitor (75-78); and Ribavirin a guanosine analogue 368 
nucleoside inhibitor (70, 79, 80) may affect transcription indirectly by blocking the 369 
biosynthesis of nucleotides. It is interesting that spiranalactone and triamterene both 370 
have the “dimmer” effect. These drugs are used clinically as diuretics that block sodium 371 
channels. It is unclear how they can affect the functions of the influenza virus core at a 372 
post-entry level. 373 
 374 
Of the 25 drugs that inhibited both H5-S-FLU and E-S-FLU, 13 reduced the number of 375 
infected cells, and thus may have inhibited cell entry by both H5 haemagglutinin and 376 
EBOV-GP. Of these Chloroquine (a lysomotropic drug) and Niclosamide may act by 377 
reducing the lysosmal proton concentration, which can influence the efficiency of 378 
cathepsin in endosome digesting EBOV-GP (81). Niclosamide is a proton ionophore 379 
(82, 83) and gave a similar IC50 on H5-S-FLU (3.3 μM) and E-S-FLU entry (1.7 μM). 380 
Arbidol may inhibit fusion of viral and lysosome membranes in a manner related to its 381 
effect on influenza haemagglutinin (84-86). Although we did not find inhibition by Arbidol 382 
of the H5 coated S-FLU, we have since confirmed inhibition of S-FLU coated with H7 383 
haemagglutinins from A/Netherlands/219/2003 and A/Shanghai/1/2013/H7, as well as 384 
H1 haemagglutinins from A/PR/8/1934 and A/England/195/2009 (Data not shown). A 385 
recent structure revealed Arbidol bound to H7 haemagglutinin from influenza (87); it 386 
may be interesting to analyse the binding of Arbidol to EBOV-GP.  387 
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In summary, we have developed a new surrogate E-S-FLU for Ebola virus. It mimics the 389 
Ebola virus at the level of cell entry and can be a valuable tool for screening antibodies, 390 
drug therapeutics as well as studying the fundamental biology of the Ebola virus entry 391 
process.  392 
 393 
Materials and Methods 394 
Pseudotyped virus design and production  395 
cDNA encoding EBOV-GP from the following species was human codon optimized and 396 
synthesized by GeneArt. (Zaire Makona wt/GIN/2014/Kissidougou-C15, Genbank: 397 
KJ660346.1). Lentiviral vector pHR-SIN (88) was engineered to incorporate the EBOV-398 
GP cDNA. We transduced Madin-Darby canine kidney epithelial cells (MDCK-SIAT1) 399 
(20) with lentivirus to express full-length EBOV-GP. 400 
 401 
Transduced cells were stained with EBOV-GP specific monoclonal antibody: KZ52 402 
specific to Zaire (34, 35), or 66-4-C12 cross-reactive to all Ebola Species (Rijal 403 
unpublished), and with a second layer of FITC-conjugated goat anti-human antibody 404 
(Life technologies ref: H10301). Stained cells were bulk sorted with a fluorescence-405 
activated cell sorter (FACS) to achieve maximal expression of EBOV-GP (E-SIAT cell 406 
line, shown in Fig. 1). EBOV-GP was detected on >99% of sorted cells and was stable 407 
and uniform up to at least to the 9th passage after sorting.  408 
 409 
E-S-FLU was generated based on a non-replicating pseudotyped influenza virus (S-410 
FLU) previously described (11, 89). We used the version that expressed enhanced 411 
 o
n







green fluorescent protein (S-eGFP), which has its S-haemagglutinin coding sequence 412 
replaced by an eGFP reporter gene. We isolated subclones of the original S-FLU that 413 
showed brighter fluorescence, and found a single mutation at T60C in the A/PR/8/34 414 
Haemagglutinin signal sequence (NCBI Reference Sequence: NC_002017.1) that 415 
abrogates an out of frame ATG, which had interfered with downstream eGFP 416 
expression. All subsequent versions of S-FLU contain this enhancement, which gives a 417 
sufficiently bright fluorescence signal from infected cells to read on the CLARIOstar® 418 
fluorescence plate reader. Seed viruses were doubly cloned by limiting dilution before 419 
seeding the E-SIAT or H5-SIAT producer cells. 420 
 421 
Seed S-FLU viruses coated in H5, H7 or H1 haemagglutinin were titrated by standard 422 
TCID50 assay on MDCK-SIAT1 cells, using fluorescence detection (as described 423 
below). Titration experiments revealed that a relatively high MOI of approximately 1 424 
TCID50 per cell of seed S-FLU virus (11) added to infect E-SIAT cells produced the 425 
highest titers of E-S-FLU, whereas lower MOI (~0.01) was adequate for seeding HA-426 
SIAT cell lines (11). Viral growth medium (VGM) was DMEM with 0.1% Bovine Albumin, 427 
10 mM HEPES, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin). After 428 
2 hours incubation of E-SIAT with seed S-FLU, any remaining seed virus was removed 429 
by a wash with PBS. Cells were then incubated in VGM medium for 48 hours at 37 oC, 430 
5% CO2 incubator without added trypsin. Culture supernatant was harvested and stored 431 
into aliquots at -80 oC. Replication of HA pseudotyped viruses required addition of 432 
trypsin as described (11). 433 
 434 
Seed Virus TCID50 435 
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Seed S-FLU viruses coated in influenza hemagglutinin were titrated for the 436 
concentration of replication competent clones (TCID50) by a standard limiting dilution 437 
method as described (Powell et al).  Wells containing clones of eGFP expressing S-FLU 438 
> 4 Standard Deviations above 16 control wells were detected by plate reader 439 
(described below), and the TCID50/ml calculated by the Reed Muench method (90).  440 
 441 
S-FLU Batch Cell Infectious Dose 50 (CID50) 442 
Batches of E-S-FLU and H5-S-FLU were titrated for infectivity of MDCK-SIAT1 indicator 443 
cells after overnight infection. Harvested culture supernatants (100 ul) containing E-S-444 
FLU or H5 S-FLU were titrated in two-fold dilutions in VGM across a flat-bottomed 96-445 
well plate (Fig. 2A). MDCK-SIAT1 indicator cells were washed in PBS, and 3x104 cells 446 
in 100ul VGM were added to each well and incubated for 18 hours (37 oC, 5% CO2). 447 
Medium was removed from the wells and cells were fixed in 10% formalin (in PBS) for 448 
30 minutes at 4 oC. The virus titer was assessed by eGFP fluorescence analyzed by 449 
plate reader (CLARIOstar®). The dilution of virus in giving 50% of the maximum plateau 450 
fluorescence signal (EC50) was calculated by linear interpolation. The EC50 dilution 451 
obtained by best fit of the titration curve to the Poisson Distribution was very similar 452 
(data not shown). Typical EC50 dilutions for E-S-FLU harvested after 48 hours were 453 
~1:8 compared to ~1: 500 for H5-S-FLU (Fig. 2). From the EC50 dilution, and the 454 
number of cells per well (3x104), the Cell Infectious Dose 50% (CID50/ml) in the E-S-455 
FLU batch was calculated as ~2X106 CID50/ml, H5 S-FLU as ~1.6x108 CID50/ml. H5-S-456 
FLU and E-S-FLU were used at a concentration for inhibition assays that gave close to 457 
maximum plateau fluorescence in infected MDCK-SIAT1 cells (MOI ~ 4 CID50/cell). 458 
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This value of was used to normalise fluorescence readout to % of maximum in the 459 
figures (Fig. 2A).   460 
 461 
In this paper, all the evaluation and screening were done on Zaire (C15) E-S-FLU and 462 
H5-S-FLU in parallel. 463 
 464 
CLARIOstar® plate reader setting 465 
Fluorescence plate readout was carried out in costar-96-well cell culture plates (costar 466 
#3799). We chose the “COSTAR 96 microplate” mode in the CLARIOstar® software. 467 
For measuring eGFP level, fluorescence excitation was at 483nm (bandwidth of 8nm) 468 
and emission at 515nm (bandwidth 8nm), with dichroic filter of 499nm. Each well had 50 469 
flashes at 4mm diameter and fluorescence readout from the top optic, giving the orbital 470 
averaging value. For measuring WGA (Alexa Fluor® 647 Conjugate) in the drug 471 
inhibition assay, fluorescence excitation was at 630nm (bandwidth of 30nm), emission 472 
at 678nm (bandwidth of 20nm). Each well had 53 flashes at 4mm and fluorescence 473 
readout from the top optic, giving the orbital averaging value. The focal length and gain 474 
were adjusted before each plate was read. Generally optimal focal length was 5.0 mm, 475 
and gain for eGFP channel was adjusted to 3000; gain for WGA-647 was adjusted to 476 
2500. 477 
 478 
E-S-FLU infection in NPC1 knockout cells  479 
Niemann Pick C1 protein (NPC1) is the key receptor for Ebola virus cell entry at the 480 
level of the lysosomal membrane (30-32). Two NPC1-knockout HeLa cell lines were 481 
generated by the CRISPR/cas9 technique (ex2 NPC1-KO and ex4 NPC1-KO, named 482 
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by the exon which was deleted). Generation and verification of the NPC1 KO cell lines 483 
have been described in Tharkeshwar et al., 2017 (33).  484 
 485 
1X105 wild-type HeLa, ex2 NPC1-KO or ex4 NPC1-KO HeLa cells were seeded to a 24-486 
well tissue culture plate in 500 μl D10 medium (DMEM + 10% foetal calf serum + 487 
penicillin and streptomycin) the night before infection. Before infection, the medium was 488 
removed and cells were washed once with PBS. Cells were infected with maximal 489 
doses of 1 x 106 CID50 E-S-FLU (MOI ~10) or 8 x 107 CID50 H5-S-FLU (MOI ~800) 490 
incubated overnight. After infection, cells were trypsinised and transferred to 5ml 491 
polypropylene tubes. Percentage infection was analyzed by counting fluorescent cells in 492 
the flow cytometer (CyAn ADP Analyzer).  493 
 494 
Micro-neutralization assay  495 
Micro-neutralization assay measures the inhibition titer of antibodies against virus entry 496 
in vitro. Assay was done as described in Powell et al., 2012 (11, 91) with minor 497 
modifications. E-S-FLU (MOI ~4) and H5-S-FLU (MOI ~4) viruses were diluted in VGM 498 
to give plateau expression of eGFP in 3X104 MDCK-SIAT1 cells after overnight infection 499 
in 96-well flat-bottomed plates. 50 μl of virus was pre-incubated with 50 μl antibody at 500 
two-fold dilutions for 2 hours. 3X104 MDCK-SIAT1 cells in 100μl VGM were then seeded 501 
to each well and allow overnight infection (37 oC, 5% CO2). After infection, medium was 502 
removed from the wells and cells were fixed with 100 μl 10% formalin (in PBS) for 30 503 
minutes at 4 oC, the formalin then replaced with 100 μl PBS. Plates were analyzed by 504 
fluorescence plate reader (CLARIOstar®) and fluorescence microscopy. The 505 
concentration of antibody or drug that gave 50% inhibition of infection (IC50%) was 506 
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calculated by linear interpolation. Monoclonal antibodies mentioned in this study: KZ52, 507 
a human monoclonal antibody that specifically binds Zaire EBOV-GP and neutralizes 508 
EBOV wild-type virus in vitro (34, 35, 92). Our version was reconstituted from the 509 
sequence published in the crystal structure PDB file: 3CSY (35). 21D85A is a human 510 
monoclonal antibody made in-house that specifically binds to H5 haemagglutinin and 511 
neutralizes H5-S-FLU. 512 
 513 
We were kindly provided with some EBOV-GP pseudotyped lentivirus (GP-lenti) from 514 
Dr. Edward Wright. GP-lenti carries a firefly luciferase reporter gene. 50 μl of GP-lenti 515 
pseudotyped viruses were pre-incubated with 50 μl antibodies in two-fold dilutions for 2 516 
hours and 3X104 MDCK-SIAT1 cells were added. Cells were incubated with virus 517 
infection in VGM for 48 hours. After 48 hours, infection was quantified by measuring the 518 
luciferase reporter expression. Medium was removed from the wells, and cells were 519 
lysed with 50 μl Glo-lysis buffer for 5 minute, then 50 μl Bright-Glo (Promega) substrate 520 
was added for 5 minute enzymatic reaction. Solutions were transferred to Opaque 521 
plates for luminescence measurement using the GloMax®-Multi Detection System 522 
(Promega). 523 
 524 
Drug inhibition assay 525 
All small inhibitor molecules, including the LOPAC®1280 library mentioned in this study 526 
were ordered from Sigma-Aldrich, and stored in 10mM DMSO at -20oC, with the 527 
exception of AY9944, which was ordered from Merck (Cat. No. 190080); and trans-528 
Ned19 (provided by our collaborator Antony Galione). Drugs were diluted in VGM to 529 
give a starting concentration of 100μM (unless stated otherwise), and then titrated in 530 
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50μl VGM in two-fold dilutions across a 96-well plate. 3X104 MDCK-SIAT1 cells were 531 
seeded in 50 μl VGM to pre-incubate with drugs for 3 hours (37oC, 5% CO2). 100μl of 532 
E-S-FLU (MOI ~4) or H5-S-FLU (MOI ~4) viruses were diluted in VGM to give plateau 533 
expression of eGFP in 3X104 MDCK-SIAT1 cells was then added for overnight infection. 534 
Cells were fixed with 100 μl 10% formalin (in PBS) for 30 minutes, the formalin was then 535 
replaced by PBS, and the plates were analyzed by fluorescence plate reader 536 
(CLARIOstar®) as for the MN assay. Infection and inhibition was quantified by 537 
measuring the eGFP expression level. IC50 of drug is the concentration at which the 538 
eGFP fluorescence signal was reduced by 50%. When more than three measurements 539 
were made for each drug, a 95% confidence interval was calculated and stated (Table 540 
1). 541 
 542 
Due to the toxicity effect of many drug molecules to cells at high concentrations, dead 543 
cells were washed away before plate reading. This may give a falsely low eGFP 544 
fluorescence reading in the plate reader, but can be detected by visual inspection in the 545 
fluorescence microscope. To estimate the number of cells remaining in each well, plates 546 
were stained with wheat germ agglutinin (WGA) after cells were fixed and washed once 547 
with phosphate-buffered saline (PBS). WGA is a lectin that binds to sialic acid and N-548 
acetylglucosaminyl residues at the cell surface. 50 μl of 5 μg/ml WGA (Alexa Fluor® 549 
647 Conjugate, Thermofisher Cat: W32466) was added to each well and incubated at 550 
room temperature for 15 minutes. Plates were then washed twice with PBS before 551 











LOPAC®1280 screen vs. Johansen et al., drug screen 554 
Johansen et al., (38) screened 2635 compounds for antiviral activity against genetically 555 
engineered Ebola virus that expresses eGFP (eGFP-EBOV) in vitro. In their 556 
supplementary table S1, they have listed all the experimental data for the small 557 
molecules they have screened in the study. Out of the 2635 molecules they tested, 538 558 
molecules were also found within the sigma LOPAC®1280 library, and were screened 559 
against E-S-FLU in our study. We have compared the inhibitory effect of these 538 560 
compounds in both screens, i.e. each molecule is either “+” (inhibited infection) or “-” 561 
(did not inhibit infection within the concentration range tested) and carried out a Fisher's 562 
exact test to measure the significance of the association. 563 
 564 
LogP and pKa calculation  565 
For the drug molecules listed in Table 1, logP (partition parameter) and pKa values 566 
(strongest basic pKa) were estimated by using MarvinSketch program, based on their 567 
chemical structure.  568 
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Figure legend: 876 
FIG 1 Stable expression of EBOV-GP protein on the surface of transduced MDCK-877 
SIAT1 cell line.  878 
FACS plots of (A) MDCK-SIAT1 and (B) MDCK-SIAT1 cells transduced with full-length 879 
GP (E-SIAT). Cells were stained with primary antibody KZ52 (anti-GP antibody) or 880 
21D85A (anti-H5 antibody), followed by a FITC-linked anti-human secondary antibody. 881 
E-SIAT cells stably express GP at the cell surface up to at least the 9th passage, which 882 
can be detected by a conformational antibody KZ52 specifically (B: blue).  883 
(C to F) Immunofluorescence pictures of MDCK-SIAT1 (C and E), E-SIAT (D and F) 884 
stained with KZ52 and FITC-linked anti-human antibody. 885 
 886 
FIG 2 Pseudotyping S-FLU with EBOV-GP. 887 
(A) E-SIAT cells were seeded with 1 TCID50 per cell of seed S-FLU virus to generate 888 
EBOV-GP (cyan) and H5 (red) pseudotyped S-FLU viruses. Parental MDCK-SIAT1 889 
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cells were also included as control. Culture supernatant (s/n) harvested after 48 hours 890 
was titrated in comparison to H5-S-FLU in two-fold dilutions on MDCK-SIAT1 indicator 891 
cells for 24 hours infection. Infected cells expressing eGFP were detected and 892 
quantified by a CLARIOstar® fluorescence plate reader. Undiluted E-S-FLU and H5-S-893 
FLU gives a saturated infection and the maximum fluorescence readout is used to 894 
calculate the infection% at lower dilutions. 895 
 (B) E-SIAT and H5-SIAT cells were seeded with 1 TCID50 per cell of seed S-FLU 896 
virus. Culture supernatant harvested at different time points post seeding were titrated 897 
on MDCK-SIAT1 cells. The EC50 is the dilution of virus giving 50% of the maximum 898 
plateau fluorescence signal and was calculated by linear interpolation. The CID50/ml is 899 
calculated from the EC50 dilution and the number of cells per well (3X104 cells). 900 
(C) 100 TCID50 seed S-FLU virus was added to 3X104 MDCK-SIAT1, E-SIAT or H5-901 
SIAT cells. Live images of representative plaques were taken by IncuCyte® every 3 902 
hours. E-SIAT supports formation of small diffuse plaque compared to the dense plaque 903 
formed in H5-SIAT cells. 904 
 905 
FIG 3 E-S-FLU requires NPC1 receptor expression for infection of HeLa cells. FACS 906 
plots of wild-type HeLa cells and two clones of NPC1 knockout HeLa cells (ex2 NPC1-907 
KO and ex4 NPC1-KO) infected by undiluted E-S-FLU and H5-S-FLU. S-FLU encodes 908 
an eGFP reporter gene. Percentage infected cells is indicated by percentage of cells 909 
with GFP readout higher than 102. 910 
 911 
FIG 4 Antibody neutralisation of pseudotyped influenza virus E-S-FLU, H5-S-FLU, and 912 
lentivirus HIV(EBOV-Z) pseudotype. 913 
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Viruses were pre-incubated for 2 hours with antibody KZ52 (anti-GP) or 21D85A (anti-914 
H5) before adding the indicator MDCK-SIAT 1 cells. Antibodies were titrated in two-fold 915 
dilutions from 10μg/ml. After 24 hours, infection was quantified by measuring the eGFP 916 
expression (influenza) or luminenscence (lentivirus). Titration curves are shown in (A), 917 
(B) and (C). EC50 of an antibody is the concentration at which infection is reduced by 918 
50%. Summary of EC50 concentrations for mAb KZ52 and 21D85A to the three 919 
pseudotyped viruses is shown in (D). Multiple EC50 values from repeat experiments are 920 
shown with their geometric mean and 95% confident intervals. 10,000 ng/ml is assigned 921 
to antibodies that did not neutralize.  922 
(E and F) Microscopy pictures (X10 objective) of assays showing specificity of micro-923 
neutralisation by antibodies. For “Virus only”, E-S-FLU and H5-S-FLU were added 924 
directly to MDCK-SIAT1 cells. Infected cells express eGFP, shown as green cells. In the 925 
MN assay, virus was pre-incubated with 10 μg/ml of monoclonal antibody KZ52 (anti-926 
GP) or 21D85A (anti-H5) before infecting MDCK-SIAT1 cells. Inhibition is visualized as 927 
significant reduced green fluorescent cells.  928 
 929 
FIG 5 Tetrandrine inhibition assay with E-S-FLU and H5-S-FLU. 930 
Tetrandrine was titrated from 100uM to 0.2uM in the drug inhibition assay against E-S-931 
FLU and H5-S-FLU. Cells were pre-incubated with Tetrandrine for 3 hours and infected 932 
by virus for 24 hours. (A) Infection% was quantified by eGFP expression measured by 933 
fluorescence plate reader. (B) WGA was added to stain cell membrane sialic acid and 934 
N-acetylglucosaminyl residues, as an estimation of cell number remaining in each well 935 
after fixation and wash. Toxicity reduces the WGA fluorescence as cells detach from the 936 
plastic. Note that the S-FLU expresses neuraminidase which partially reduces WGA 937 
 o
n







binding in (B). Neutralisation of S-FLU is associated with some increase in WGA binding 938 
as neuraminidase expression is reduced. 939 
(C and D) Microscopy pictures of Tetrandrine inhibition assay. Note that toxicity of 940 
Tetrandrine at 25uM resulted in reduction in cells in the brightfield channel. 941 
 942 
FIG 6 Groups of drugs from the LOPAC1280 library inhibited E-S-FLU. 215 out of 1280 943 
small molecules inhibited E-S-FLU infection. They were grouped and displayed 944 
according to their pharmacological activities. Number displayed indicate number of drug 945 
molecules inhibited E-S-FLU from this group. 946 
 947 
FIG 7 Summary of all the drugs (228 molecules) that have inhibited E-S-FLU in this 948 
study. This includes 215 inhibitors from LOPAC1280 library and 13 additional inhibitors 949 
tested. 25 molecules inhibited H5-S-FLU, all of which also inhibited E-S-FLU. The 950 
inhibitors were ranked and plotted according to their IC50 concentration, at which 50% 951 
of the virus infection is inhibited. (Titration example shown in Fig. 5). Detailed 952 
information of the inhibitors are listed in supplementary Table S1. 953 
 954 
FIG 8 Ebola virus cell entry mechanism (adapted from J White and K Schornberg 2012 955 
Nature Rev. Microbiol) and potential drug mode of actions. 956 
 957 
Table 1 IC50 of 13 drugs that inhibited E-S-FLU infection selected from the literature 958 
 959 
Table 2 Comparison of overlapping set of drugs between LOPAC1280 library and the 960 
collection of Johansen et al., 2015 (39). 961 
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538 drug molecules appeared in both our LOPAC1280 library screen and the Johansen 962 
et al., 2015’s screen. “+” indicates the number of inhibitors, and “–” indicates the non-963 
inhibitors. Association between two screens are calculated by two-tailed Fisher’s exact 964 
test. 965 
 966 
Table 3 25 small molecules that inhibited both E-S-FLU and H5-S-FLU in this study. (22 967 
come from LOPAC1280 library). 968 
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n





































































































































































Table 2 Comparison of overlapping set of drugs between LOPAC1280 library and 









538 drug molecules appeared in both our LOPAC1280 library screen and the 
Johansen et al., 2015’s screen. “+” indicates the number of inhibitors, and “–” 
indicates the non-inhibitors. Association between two screens are calculated by two-
tailed Fisher’s exact test. 
  
Two-tailed Fisher's exact test 
 
Johansen + Johansen - Total 
LOPAC + 23 70 93 
LOPAC - 26 419 445 
Total 49 489 538 
P value: < 0.0001 
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Table 3. 25 small molecules that has inhibited both E-S-FLU and H5-S-FLU in this 

















5 12-G4 O3125 Ouabain 1.5 0.28 0.3 reduced 
7 14-B2 R1402 Raloxifene HCl 50 0.40 33.8 reduced 
14 11-G7 N3510 Niclosamide 25 1.69 3.2 reduced 
21   U3633 U18666A 100 2.56 49.5 reduced 
27 04-B11 C8903 Clemastine fumarate salt 100 3.40 58.4 reduced 
35   SML0445 Clemastine 50 4.30 50.0 reduced 
42 04-F7 C6628 Chloroquine diphosphate 200 5.44 67.0 reduced 
48 03-B7 PZ0171 CP-100356 monohydrochloride 50 6.80 20.0 reduced 
54 02-H5 A9809 Amsacrine hydrochloride 25 7.68 6.76 reduced 
61 02-E10 A255 A-77636 hydrochloride 25 8.60 15.6 reduced 
63 08-E9 H127 Hexahydro-sila-difenidol hydrochloride, p-fluoro analog 100 9.30 65.0 reduced 
70 12-E7 L9793 LP44 100 10.40 70.0 reduced 
118 02-C7 PZ0178 PHA 767491 hydrochloride 25 21.30 15.7 reduced 
2 01-D5 A1784 Aminopterin 100 0.20 0.2 dimmer 
11 02-C11 SML0113 Brequinar sodium salt hydrate 100 1.30 1.4 dimmer 
19 04-D3 C3930 Calmidazolium chloride 6.25 2.30 3.9 dimmer 
20 03-D6 G6423 Gemcitabine hydrohloride 100 2.50 1.9 dimmer 
60 05-D6 D0670 Dihydroouabain 25 8.30 5.7 dimmer 
104 13-B10 SML0678 Pyridostatin trifluoroacetate slt 200 17.40 58.8 dimmer 
135 05-B9 D3768 Dequalinium chloride hydrate 100 27.30 12.1 dimmer 
145 14-C9 S3378 Spironolactone 100 30.40 33.1 dimmer 




Faviparivir (T705) 500 39.30 67.3 dimmer 
209 15-H7 T4143 Triamterene 200 85.20 132.3 dimmer 
222 15-A8 T4182 Tyrphostin AG 1478 200 115.30 141.0 dimmer 
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